LACTOLOGY FOUNDATION

Ispaghula-containing fixed-dose combinations in ATC class A06AC51 are bulk-forming laxatives used for constipation and related conditions; in breastfeeding, ispaghula (psyllium) itself is considered compatible because it is not systemically absorbed, whereas co‑administered active substances (for example mebeverine) require individual benefit–risk assessment and usually short-term, lowest-effective-dose use in lactating women.medpedia.framar+4

Pharmacological class and composition

Ispaghula combinations (A06AC51) contain ispaghula (psyllium) husk as the main component, often combined with other agents such as the antispasmodic mebeverine hydrochloride. These preparations are classified as bulk-forming laxatives in the gastrointestinal system ATC group A06AC and are available as sachets or granules for oral suspension.hpra+4

Mechanism of action

Ispaghula husk is a hydrophilic plant fibre that absorbs water in the intestinal lumen, increasing stool bulk and moisture, which stimulates peristalsis and facilitates softer, more voluminous stools. In combinations, added antispasmodics such as mebeverine provide direct smooth-muscle relaxation in the gut wall, reducing abdominal cramping and other functional bowel symptoms associated with constipation or irritable bowel syndrome.bnf.nice+5

Indications and clinical use

Ispaghula combinations are indicated for the treatment of habitual constipation and in conditions where softened stools are clinically desirable, including anal fissures, haemorrhoids, and the postoperative period after anorectal or rectal surgery. Some products are also used in functional bowel disorders such as irritable bowel syndrome with predominant constipation, where they address both stool consistency and colicky pain.truemeds+5

Pharmacokinetics and systemic exposure

Psyllium/ispaghula husk is not absorbed from the gastrointestinal tract; it remains within the gut lumen and is either excreted unchanged or partially fermented by colonic microbiota to short-chain fatty acids. Because systemic exposure is negligible, transfer of ispaghula into breast milk is not expected, and systemic maternal adverse effects are uncommon except in cases of significant fluid restriction, obstruction, or hypersensitivity.seslhd.nsw+2

In contrast, co‑formulated agents such as mebeverine are orally absorbed, undergo first-pass metabolism, and can reach low concentrations in systemic circulation and breast milk. Available data suggest low levels of mebeverine in breast milk and a low likelihood of clinically relevant effects in breastfed infants, but evidence is limited and product information often recommends caution or avoidance during lactation.medex+3

General adverse effects

Typical adverse effects of ispaghula include flatulence, abdominal distension, and, if taken with insufficient fluid, the risk of fecal impaction or esophageal/intestinal obstruction. Hypersensitivity reactions (rhinitis, conjunctivitis, bronchospasm, urticaria, and rarely anaphylaxis) have been reported, particularly in sensitized individuals or healthcare workers exposed to ispaghula dust.ema.europa+2

Combination partners contribute their own adverse-event profiles; for mebeverine these may include gastrointestinal dyspepsia, constipation or diarrhoea, dizziness, and rare hypersensitivity reactions. Overdose with ispaghula typically presents with gastrointestinal symptoms related to obstruction, while mebeverine overdose reports mainly involve supportive management without a specific antidote.medsafe+2

Toxicity in special populations

In otherwise healthy adults, ispaghula has been shown to improve bowel habit parameters such as stool frequency and reduced straining without significant systemic toxicity. However, ispaghula is contraindicated in patients with known gastrointestinal obstruction, stenosis, or undiagnosed rectal bleeding, as well as in those with severe dysphagia or other conditions predisposing to aspiration.pubmed.ncbi.nlm.nih+2

In patients with functional bowel disorders or irritable bowel syndrome, combinations with antispasmodics may improve abdominal pain and bloating, but inappropriate use in patients with organic disease (for example inflammatory bowel disease) may delay diagnosis and increase risk of complications. Dose titration and adequate fluid intake are particularly important in elderly patients and those on concomitant constipating drugs to minimize the risk of impaction or obstruction.truemeds+3

Drug–drug interactions and administration considerations

Bulk-forming agents can reduce or delay absorption of co‑administered oral medications by trapping them within the fibre matrix; for this reason, ispaghula combinations should generally be taken at least 30–60 minutes before or after other oral drugs. Concomitant use with other laxatives is usually unnecessary and may increase the risk of diarrhoea or electrolyte imbalance, so combination regimens should be individualized.breastfeedingnetwork+2

Adequate fluid intake is mandatory during treatment, as ingestion of ispaghula with insufficient water can lead to esophageal or intestinal obstruction and worsening constipation. Patients should be counselled to avoid taking ispaghula immediately before bedtime because recumbency may increase the risk of esophageal impaction in case of inadequate fluid intake.seslhd.nsw+1

Use in pregnancy

Clinical and regulatory guidance states that ispaghula husk may be considered for constipation during pregnancy when non-pharmacological measures (dietary fibre, hydration, physical activity) are insufficient, given its lack of systemic absorption and long-standing clinical experience. Combination products that include pharmacologically active partners such as mebeverine are generally used with caution or avoided in pregnancy due to limited safety data and the availability of single-ingredient ispaghula preparations.doctorfox+5

Lactation-specific considerations

Because psyllium/ispaghula is not absorbed from the gastrointestinal tract, it does not enter breast milk, and multiple authoritative sources consider it compatible with breastfeeding. Breastfeeding organizations and clinical guidelines frequently list bulk-forming laxatives such as psyllium as first-line pharmacological options for postpartum constipation in nursing mothers, alongside dietary and lifestyle interventions.nhs+4

For fixed-dose combinations containing ispaghula and mebeverine, available information suggests that maternal use leads to low and likely clinically insignificant levels of mebeverine in breast milk; nonetheless, manufacturers and some prescribers recommend caution, emphasizing that such products should be used only when clearly indicated and for the shortest duration at the lowest effective dose. In breastfed infants, theoretical concerns relate to potential exposure to mebeverine metabolites, so monitoring for non-specific symptoms such as poor feeding, irritability, or diarrhoea is advisable if the mother continues therapy during lactation.nhs+3

Lactation risk assessment and recommendations

Single-ingredient ispaghula bulk-forming laxatives are generally considered low-risk and compatible with breastfeeding, provided they are taken with adequate fluids and within recommended doses. Fixed-dose ispaghula combinations with absorbed co‑actives such as mebeverine have a higher uncertainty due to limited lactation data, and their use in breastfeeding women should be reserved for cases where monotherapy with ispaghula or non-pharmacological measures are insufficient, after discussing benefits and potential risks.ncbi.nlm.nih+6

When such combinations are required, clinicians should prefer short-term therapy, avoid unnecessary high doses, and consider timing doses immediately after breastfeeding to minimize peak milk concentrations of absorbed components. In addition, non-pharmacological strategies—high-fibre diet, increased fluid intake, and physical activity—should be routinely recommended to all breastfeeding women to reduce the need for prolonged laxative therapy.nhs+3

Monitoring and counselling in breastfeeding

For mothers, counselling should focus on correct preparation of ispaghula combinations (dispersing granules in sufficient water), adherence to timing relative to other medications, and recognition of warning signs such as chest pain, difficulty swallowing, severe abdominal pain, or lack of bowel movement, which may indicate obstruction and require discontinuation. Breastfeeding women using ispaghula combinations that include systemically absorbed agents should be informed about the limited evidence base, advised to report any unusual symptoms in the infant, and reassured that current data suggest a low likelihood of serious adverse events when products are used appropriately.ema.europa+4